Panbela Therapeutics, Inc. (PBLA)
USD 0.26
(-3.7%)
USD 0.26
(-3.7%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 11.8 Million USD | 137.08% |
| 2022 | 4.97 Million USD | -61.33% |
| 2021 | 12.87 Million USD | 31.17% |
| 2020 | 9.81 Million USD | 212.12% |
| 2019 | 3.14 Million USD | 65.65% |
| 2018 | 1.89 Million USD | 147.46% |
| 2017 | 767 Thousand USD | -12.54% |
| 2016 | 877 Thousand USD | -51.49% |
| 2015 | 1.8 Million USD | 344.1% |
| 2014 | 407.11 Thousand USD | -23.51% |
| 2013 | 532.26 Thousand USD | -12.87% |
| 2012 | 610.9 Thousand USD | 140.72% |
| 2011 | 253.78 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 10.52 Million USD | -10.8% |
| 2024 Q2 | 9.41 Million USD | -10.57% |
| 2023 Q4 | 11.8 Million USD | 11.05% |
| 2023 Q2 | 19.55 Million USD | 18.67% |
| 2023 Q3 | 10.62 Million USD | -45.64% |
| 2023 FY | 11.8 Million USD | 137.08% |
| 2023 Q1 | 16.47 Million USD | 230.96% |
| 2022 FY | 4.97 Million USD | -61.33% |
| 2022 Q2 | 6.55 Million USD | -40.86% |
| 2022 Q3 | 4.86 Million USD | -25.77% |
| 2022 Q4 | 4.97 Million USD | 2.28% |
| 2022 Q1 | 11.08 Million USD | -13.86% |
| 2021 Q1 | 8.89 Million USD | -9.37% |
| 2021 FY | 12.87 Million USD | 31.17% |
| 2021 Q4 | 12.87 Million USD | -13.04% |
| 2021 Q3 | 14.8 Million USD | 102.91% |
| 2021 Q2 | 7.29 Million USD | -17.98% |
| 2020 Q1 | 2.13 Million USD | -32.06% |
| 2020 Q3 | 11.48 Million USD | 245.73% |
| 2020 Q2 | 3.32 Million USD | 55.52% |
| 2020 Q4 | 9.81 Million USD | -14.56% |
| 2020 FY | 9.81 Million USD | 212.12% |
| 2019 Q4 | 3.14 Million USD | -17.7% |
| 2019 Q1 | 1.91 Million USD | 0.68% |
| 2019 FY | 3.14 Million USD | 65.65% |
| 2019 Q2 | 1.33 Million USD | -29.93% |
| 2019 Q3 | 3.82 Million USD | 185.29% |
| 2018 Q3 | 945 Thousand USD | -39.07% |
| 2018 Q4 | 1.89 Million USD | 100.85% |
| 2018 FY | 1.89 Million USD | 147.46% |
| 2018 Q1 | 1.82 Million USD | 137.94% |
| 2018 Q2 | 1.55 Million USD | -15.01% |
| 2017 Q4 | 767 Thousand USD | -49.97% |
| 2017 Q2 | 1.87 Million USD | -37.59% |
| 2017 Q1 | 3 Million USD | 243.1% |
| 2017 FY | 767 Thousand USD | -12.54% |
| 2017 Q3 | 1.53 Million USD | -18.37% |
| 2016 Q1 | 1.45 Million USD | -19.69% |
| 2016 FY | 877 Thousand USD | -51.49% |
| 2016 Q2 | 2.14 Million USD | 47.66% |
| 2016 Q4 | 877 Thousand USD | -46.72% |
| 2016 Q3 | 1.64 Million USD | -23.23% |
| 2015 Q1 | 350.68 Thousand USD | -13.86% |
| 2015 FY | 1.8 Million USD | 344.1% |
| 2015 Q4 | 1.8 Million USD | -11.42% |
| 2015 Q3 | 2.04 Million USD | 937.5% |
| 2015 Q2 | 196.72 Thousand USD | -43.9% |
| 2014 Q4 | 407.11 Thousand USD | 36.84% |
| 2014 Q1 | 440.96 Thousand USD | -17.15% |
| 2014 Q3 | 297.51 Thousand USD | -21.96% |
| 2014 FY | 407.11 Thousand USD | -23.51% |
| 2014 Q2 | 381.23 Thousand USD | -13.55% |
| 2013 Q3 | 533.3 Thousand USD | -5.27% |
| 2013 Q4 | 532.26 Thousand USD | -0.2% |
| 2013 Q1 | 572.75 Thousand USD | -6.25% |
| 2013 FY | 532.26 Thousand USD | -12.87% |
| 2013 Q2 | 562.99 Thousand USD | -1.7% |
| 2012 FY | 610.9 Thousand USD | 140.72% |
| 2012 Q4 | 610.9 Thousand USD | 0.0% |
| 2011 FY | 253.78 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| America Great Health | 299.12 Thousand USD | -3845.455% |
| Ampio Pharmaceuticals, Inc. | 5.73 Million USD | -105.753% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | 19.687% |
| Biora Therapeutics, Inc. | 31.21 Million USD | 62.191% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -266.522% |
| Better Therapeutics, Inc. | 22.94 Million USD | 48.559% |
| Calithera Biosciences, Inc. | 28.67 Million USD | 58.844% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -216.653% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | 42.553% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | 44.127% |
| Evelo Biosciences, Inc. | 64.44 Million USD | 81.686% |
| Evolutionary Genomics, Inc. | 2.35 Million USD | -401.421% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | 83.377% |
| Galera Therapeutics, Inc. | 26.14 Million USD | 54.853% |
| Innovation1 Biotech Inc. | 75.99 Thousand USD | -15430.378% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | 3.016% |
| Molecular Templates, Inc. | 35.38 Million USD | 66.645% |
| Navidea Biopharmaceuticals, Inc. | 4.37 Million USD | -169.969% |
| NexImmune, Inc. | 8.59 Million USD | -37.329% |
| Orgenesis Inc. | 14.55 Million USD | 18.898% |
| Point of Care Nano-Technology, Inc. | 124.64 Thousand USD | -9368.642% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | -107.767% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -2908.68% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | 97.504% |
| Statera Biopharma, Inc. | 21.16 Million USD | 44.25% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | -16.794% |
| Trevena, Inc. | 40.6 Million USD | 70.935% |
| Vaxxinity, Inc. | 44.35 Million USD | 73.391% |
| Vaccinex, Inc. | 3.63 Million USD | -225.034% |
| Vicapsys Life Sciences, Inc. | 39.65 Thousand USD | -29660.944% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | 79.182% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -2023.75% |